{"hands_on_practices": [{"introduction": "Understanding the fundamental patterns of inheritance is the cornerstone of genetic counseling. This practice focuses on calculating recurrence risk, a central task in helping families understand the chances of a genetic condition appearing in future offspring. By working through a classic X-linked recessive inheritance scenario, you will apply core Mendelian principles to a practical problem and explore the biological mechanism of X-inactivation, which explains why female carriers can sometimes show symptoms. [@problem_id:5039811]", "problem": "A family presents for genetic counseling regarding a heritable cause of intellectual disability (ID). The condition is known to follow an X-linked recessive mode of inheritance with complete penetrance in males and negligible de novo mutation rate for this gene. The proband is an affected male ($\\text{ID}^{+}$), his father is clinically unaffected, and his mother is heterozygous for the pathogenic variant (a confirmed carrier). Assume independent assortment of sex chromosomes and fair meiosis, so that maternal alleles segregate with equal probability and sex determination is equivalent to a fair coin flip. There is no germline mosaicism and the variant does not impair fertility. \n\nUsing only the foundational principles of Mendelian inheritance and probability, compute the conditional recurrence risk that the next child will be affected given that the next child is male. Express your final answer as an exact value with no rounding.\n\nThen, briefly explain from first principles how X-inactivation (lyonization) in heterozygous daughters can lead to variable expressivity of an X-linked recessive variant, including the concept of skewed X-inactivation and whether such skewing alters the calculated conditional recurrence risk for a male child.", "solution": "The problem is valid as it is scientifically grounded in Mendelian genetics, well-posed, and contains all necessary information for a unique solution.\n\nThe problem asks for two distinct items: first, the calculation of a conditional recurrence risk, and second, an explanation of a related biological mechanism. I will address these in sequence.\n\nPart 1: Calculation of Conditional Recurrence Risk\n\nThe problem asks for the conditional probability that the next child will be affected, given that the child is male. This can be formally stated as computing $P(\\text{Affected} | \\text{Male})$. We proceed from the foundational principles of Mendelian genetics.\n\nLet $X^A$ represent the chromosome carrying the normal (unaffected) allele and $X^a$ represent the chromosome carrying the pathogenic, recessive allele that causes intellectual disability. The Y chromosome, denoted as $Y$, does not carry this gene.\n\nBased on the information provided, we can deduce the genotypes of the parents:\n- The father is clinically unaffected. Since males are hemizygous for X-linked genes, his genotype must be $X^A Y$.\n- The mother is a confirmed heterozygous carrier. Her genotype is therefore $X^A X^a$.\n- The existence of an affected male child (the proband) with genotype $X^a Y$ is consistent with these parental genotypes, as he would have inherited the $X^a$ from his mother and the $Y$ from his father.\n\nAccording to Mendelian principles of segregation and independent assortment, we can determine the probability of each possible genotype for their offspring. The mother ($X^A X^a$) produces two types of oocytes with equal probability, one containing $X^A$ and the other containing $X^a$, each with a probability of $\\frac{1}{2}$. The father ($X^A Y$) produces two types of sperm, one containing $X^A$ and the other containing $Y$, each with a probability of $\\frac{1}{2}$.\n\nThe sample space of possible offspring genotypes and their associated probabilities is as follows:\n- Daughter, homozygous normal ($X^A X^A$): $P(X^A_{\\text{mother}}) \\times P(X^A_{\\text{father}}) = \\frac{1}{2} \\times \\frac{1}{2} = \\frac{1}{4}$. The phenotype is unaffected.\n- Daughter, heterozygous carrier ($X^A X^a$): $P(X^a_{\\text{mother}}) \\times P(X^A_{\\text{father}}) = \\frac{1}{2} \\times \\frac{1}{2} = \\frac{1}{4}$. The phenotype is typically unaffected for a recessive condition.\n- Son, unaffected ($X^A Y$): $P(X^A_{\\text{mother}}) \\times P(Y_{\\text{father}}) = \\frac{1}{2} \\times \\frac{1}{2} = \\frac{1}{4}$. The phenotype is unaffected.\n- Son, affected ($X^a Y$): $P(X^a_{\\text{mother}}) \\times P(Y_{\\text{father}}) = \\frac{1}{2} \\times \\frac{1}{2} = \\frac{1}{4}$. The phenotype is affected, as penetrance is complete in males.\n\nWe are asked to find the conditional probability of the child being affected, given that the child is male. Let event $E$ be \"the child is affected\" and event $M$ be \"the child is male\". We need to compute $P(E|M)$.\n\nFrom the definition of conditional probability, $P(E|M) = \\frac{P(E \\cap M)}{P(M)}$.\n\nFirst, we determine the probability of the event $M$, that the child is male. The male genotypes are $X^A Y$ and $X^a Y$.\n$P(M) = P(X^A Y) + P(X^a Y) = \\frac{1}{4} + \\frac{1}{4} = \\frac{1}{2}$. This aligns with the stated assumption that sex determination is a fair coin flip.\n\nNext, we determine the probability of the intersection event $E \\cap M$, that the child is both affected and male. This corresponds only to the genotype $X^a Y$.\n$P(E \\cap M) = P(X^a Y) = \\frac{1}{4}$.\n\nNow we can compute the conditional probability:\n$$P(E|M) = \\frac{P(E \\cap M)}{P(M)} = \\frac{\\frac{1}{4}}{\\frac{1}{2}} = \\frac{1}{4} \\times \\frac{2}{1} = \\frac{1}{2}$$\nThus, the recurrence risk for an affected child, given the child is male, is $\\frac{1}{2}$.\n\nPart 2: Explanation of X-Inactivation and its Implications\n\nThe second part of the query requires an explanation of X-inactivation (lyonization) and its potential relation to the calculated risk.\n\nX-inactivation is a fundamental biological process of dosage compensation in mammals. Since females possess two X chromosomes ($XX$) and males possess one ($XY$), a mechanism is required to equalize the expression levels of X-linked genes between the sexes. Early in female embryonic development, one of the two X chromosomes in each somatic cell is randomly chosen and transcriptionally silenced. This inactivated X chromosome condenses into a compact structure known as a Barr body and remains inactive in all descendant cells of that lineage. The choice of which X chromosome (maternally or paternally inherited) to inactivate is random in each cell of the early embryo.\n\nThis process has a significant consequence for females who are heterozygous for an X-linked allele, such as the carrier mother ($X^A X^a$) in this problem. Such a female is a functional mosaic, composed of two distinct cell populations. In approximately $50\\%$ of her somatic cells, the paternal X chromosome (in this case, $X^A$) will be active while the maternal X chromosome ($X^a$) is inactive. In the other $50\\%$ of her cells, the maternal $X$ chromosome ($X^a$) will be active while the paternal one ($X^A$) is inactive.\n\nThis mosaicism is the basis for variable expressivity of X-linked traits in heterozygous females. If the inactivation ratio is balanced (approximately $50:50$), a female carrier of a recessive pathogenic allele like $X^a$ will typically produce enough normal protein from the cells expressing $X^A$ to remain asymptomatic. However, if the random inactivation process results in a significant deviation from this $50:50$ ratio, it is termed skewed X-inactivation. For instance, if by stochastic chance, the X chromosome carrying the normal allele ($X^A$) is preferentially inactivated in a large proportion of cells in a critical tissue, the female will predominantly express the pathogenic allele ($X^a$). This can lead her to exhibit symptoms of the disorder, a phenomenon known as being a \"manifesting heterozygote\". The clinical severity can range from mild to severe, depending on the degree of skewing and the tissues involved.\n\nCrucially, the question asks whether such skewing alters the calculated recurrence risk for a male child. The answer is no. X-inactivation is a somatic event that determines gene expression patterns in the body cells of the mother. It does not alter the genetic constitution of her germline cells (the oocytes). The process of meiosis in the female germline is independent of the somatic inactivation pattern. The problem correctly specifies fair meiosis, meaning that during oogenesis, the mother's two X chromosomes, $X^A$ and $X^a$, will segregate into her gametes with equal probability. Therefore, any given oocyte has a $\\frac{1}{2}$ chance of containing the $X^A$ chromosome and a $\\frac{1}{2}$ chance of containing the $X^a$ chromosome. The probability that a son inherits the $X^a$ allele remains exactly $\\frac{1}{2}$, regardless of the X-inactivation pattern in his mother's somatic tissues. The mother's own phenotype, whether asymptomatic or manifesting due to skewed inactivation, has no bearing on the probabilities of allele transmission to her offspring.", "answer": "$$\\boxed{\\frac{1}{2}}$$", "id": "5039811"}, {"introduction": "Moving from the scale of a single family to an entire population requires a different set of tools. This exercise introduces the Hardy-Weinberg equilibrium principle, a foundational concept in population genetics that serves as a baseline for understanding allele frequencies. You will use it to estimate the frequency of carriers for a rare autosomal recessive disorder, a calculation with significant implications for genetic screening programs and public health policy, while also critically examining the real-world limitations of this idealized model. [@problem_id:5039715]", "problem": "A clinic is evaluating an autosomal recessive intellectual disability due to biallelic loss-of-function mutations in a single gene. In a large, panmictic population, the birth prevalence of the condition is observed to be $q^{2} = \\frac{1}{40{,}000}$, where $q$ is the frequency of the pathogenic allele and $q^{2}$ is the frequency of homozygous affected individuals. Assume Hardy–Weinberg equilibrium in this population.\n\nUsing only core definitions of allele frequency and genotype frequency under Hardy–Weinberg equilibrium for a single bi-allelic locus, derive the exact carrier frequency of this condition in the population and express your final result as a decimal. Round your answer to four significant figures.\n\nAs part of your reasoning, justify each step from first principles and briefly explain the scientific limitations of applying Hardy–Weinberg equilibrium to autosomal recessive forms of intellectual disability in real populations.", "solution": "The problem is valid as it is scientifically grounded, well-posed, and contains all necessary information for a solution.\n\nLet us define the alleles for the single gene locus in question. Let $A$ be the normal (wild-type) allele and $a$ be the pathogenic (recessive) allele. The frequencies of these alleles in the population are denoted by $p$ and $q$, respectively.\nFrequency of allele $A$ is $p$.\nFrequency of allele $a$ is $q$.\nSince this is a bi-allelic system, the sum of the allele frequencies must equal $1$:\n$$p + q = 1$$\n\nThe Hardy–Weinberg principle states that in a large, randomly mating population free from other evolutionary influences (mutation, selection, gene flow), the allele and genotype frequencies will remain constant from generation to generation. The genotype frequencies are given by the terms of the binomial expansion of $(p+q)^2$:\n$$(p + q)^2 = p^2 + 2pq + q^2 = 1$$\n\nThe terms in this expansion correspond to the frequencies of the three possible genotypes:\n- $p^2$: The frequency of homozygous normal individuals (genotype $AA$). These individuals are phenotypically unaffected.\n- $2pq$: The frequency of heterozygous individuals (genotype $Aa$). These individuals are carriers of the pathogenic allele but are phenotypically unaffected because the condition is recessive. This is the carrier frequency we need to calculate.\n- $q^2$: The frequency of homozygous recessive individuals (genotype $aa$). These individuals are affected by the intellectual disability.\n\nThe problem provides the birth prevalence of the condition, which is the frequency of homozygous affected individuals.\nGiven:\n$$q^2 = \\frac{1}{40{,}000}$$\n\nFrom this information, we can calculate the frequency of the pathogenic allele, $q$:\n$$q = \\sqrt{q^2} = \\sqrt{\\frac{1}{40{,}000}} = \\frac{\\sqrt{1}}{\\sqrt{40{,}000}} = \\frac{1}{200}$$\n\nAs a decimal, this is:\n$$q = 0.005$$\n\nNext, we can calculate the frequency of the normal allele, $p$, using the relationship $p+q=1$:\n$$p = 1 - q = 1 - \\frac{1}{200} = \\frac{200}{200} - \\frac{1}{200} = \\frac{199}{200}$$\n\nAs a decimal, this is:\n$$p = 1 - 0.005 = 0.995$$\n\nThe problem asks for the carrier frequency, which is the frequency of heterozygous individuals, given by the term $2pq$. We can now substitute the derived values of $p$ and $q$ into this expression:\n$$\\text{Carrier Frequency} = 2pq = 2 \\times \\left(\\frac{199}{200}\\right) \\times \\left(\\frac{1}{200}\\right)$$\n\nPerforming the multiplication:\n$$2pq = \\frac{2 \\times 199}{200 \\times 200} = \\frac{199}{100 \\times 200} = \\frac{199}{20{,}000}$$\n\nTo express this result as a decimal, we perform the division:\n$$\\frac{199}{20{,}000} = 0.00995$$\n\nThe problem requires the final answer to be rounded to four significant figures. The number $0.00995$ has three significant figures (the digits $9, 9, 5$). To express it with four significant figures, we must add a trailing zero.\n$$\\text{Carrier Frequency} \\approx 0.009950$$\n\nThis result means that approximately $1$ in $\\frac{1}{0.00995} \\approx 100.5$ people in this population are carriers of the pathogenic allele.\n\nNow, we address the scientific limitations of applying Hardy–Weinberg equilibrium to this scenario. The HWE model is an idealization that relies on several strict assumptions, which are often violated in real human populations, particularly in the context of genetic diseases.\n\n1.  **Non-random Mating**: HWE assumes panmixia, or random mating. However, human populations often exhibit non-random mating patterns. For rare recessive disorders, the most significant deviation is **consanguinity** (mating between relatives). Consanguineous unions increase the probability that two carriers will have children, leading to a higher incidence of affected offspring ($aa$) than predicted by HWE for the population as a whole. This is because relatives are more likely to share the same rare pathogenic alleles inherited from a common ancestor. While consanguinity increases homozygosity, it does not change the overall allele frequencies ($p$ and $q$) in the population.\n\n2.  **Natural Selection**: HWE assumes no selection, meaning all genotypes have equal survival and reproductive rates. This is a major oversimplification for a condition described as an \"intellectual disability\". Individuals with a severe form of intellectual disability may have reduced reproductive fitness (i.e., fewer or no offspring). This constitutes **negative selection** against the $aa$ genotype. Over many generations, this selection would tend to reduce the frequency of the pathogenic allele $q$.\n\n3.  **New Mutations**: The model assumes no new mutations occur. In reality, new mutations can arise spontaneously, reintroducing the pathogenic allele $a$ into the gene pool. For severe recessive conditions subject to negative selection, the prevalence of the allele in the population often reflects a **mutation-selection balance**, where the rate of elimination of the allele by selection is balanced by its rate of creation through new mutation. HWE does not account for this dynamic.\n\n4.  **Population Size (Genetic Drift)**: HWE is strictly valid only for an infinitely large population. While the problem specifies a \"large\" population, all real populations are finite. In finite populations, allele frequencies can change randomly from one generation to the next due to chance events, a process known as **genetic drift**. Drift can lead to the loss of rare alleles or their fixation, especially in smaller, reproductively isolated subpopulations (e.g., founder effects).\n\n5.  **Gene Flow (Migration)**: The model assumes a closed population with no migration. Real populations experience gene flow from other populations. If a migrant population has a different frequency of the allele $q$, migration will alter the allele frequencies in the host population, disrupting the equilibrium.\n\nIn summary, while the HWE calculation provides a useful first-order approximation, its application to a real-world scenario like an autosomal recessive intellectual disability is limited by violations of its core assumptions, most notably non-random mating (consanguinity) and negative selection.", "answer": "$$ \\boxed{0.009950} $$", "id": "5039715"}, {"introduction": "Modern genetic diagnosis is rarely a simple \"yes or no\" answer; it is a process of probabilistic reasoning. This advanced practice simulates the thought process of a clinical geneticist who must interpret complex genomic data. You will use Bayes' theorem to update the probability of different genetic causes for a patient's intellectual disability after receiving results from a trio exome sequencing, demonstrating how prior knowledge is formally combined with new evidence to arrive at the most likely diagnosis. [@problem_id:5039762]", "problem": "A non-consanguineous child presents with severe intellectual disability, early-onset epilepsy, and multiple dysmorphic features. Before any genomic testing, a clinician wishes to formalize etiologic priors across three mutually exclusive classes: copy number variant (CNV), de novo single nucleotide variant (SNV), and autosomal recessive biallelic variants (recessive). Based on epidemiologic data for similar phenotypes in outbred populations, assume the following prior probabilities: $P(\\text{CNV}) = 0.20$, $P(\\text{de novo SNV}) = 0.50$, and $P(\\text{recessive}) = 0.30$.\n\nTrio exome sequencing is then performed and reports a single high-confidence de novo protein-truncating variant consistent with loss-of-function (LoF) in a gene with strong intolerance to LoF (a constrained gene). No other candidate variants are reported. For the purpose of probabilistic inference, take the following quantities as established from large-cohort observations and assay performance:\n\n- Among true de novo SNV etiologies for this phenotype class, the fraction in which the causal event presents as a de novo LoF in a constrained gene is $f = 0.60$. The analytical sensitivity of the exome assay to detect such LoF variants is $s = 0.98$.\n- In individuals whose true etiology is not a de novo SNV (that is, CNV or recessive), the background probability per trio exome of observing at least one incidental de novo LoF in a constrained gene is $r = 2 \\times 10^{-3}$, and the detection probability for such an LoF is again $s = 0.98$.\n\nLet $E$ denote the event “the trio exome reports a de novo LoF in a constrained gene.” Using the information above and standard rules of probability applied to mutually exclusive hypotheses, compute the posterior probability $P(\\text{de novo SNV} \\mid E)$. Round your answer to $4$ significant figures and express it as a decimal without a percent sign.", "solution": "The problem requires the computation of a posterior probability, $P(\\text{de novo SNV} \\mid E)$, given a set of prior probabilities and conditional likelihoods for a specific piece of evidence. This is a direct application of Bayes' theorem.\n\nFirst, we formalize the components of the problem. Let the set of mutually exclusive etiological hypotheses be $\\mathcal{H} = \\{\\text{CNV}, \\text{de novo SNV}, \\text{recessive}\\}$. The prior probabilities for these hypotheses are given as:\n$P(\\text{CNV}) = 0.20$\n$P(\\text{de novo SNV}) = 0.50$\n$P(\\text{recessive}) = 0.30$\nThe sum of these priors is $0.20 + 0.50 + 0.30 = 1.00$, as required for a complete set of mutually exclusive hypotheses.\n\nLet $E$ be the event that \"the trio exome reports a de novo LoF in a constrained gene.\" We are tasked with finding the posterior probability $P(\\text{de novo SNV} \\mid E)$.\n\nAccording to Bayes' theorem, this posterior probability is given by:\n$$P(\\text{de novo SNV} \\mid E) = \\frac{P(E \\mid \\text{de novo SNV}) P(\\text{de novo SNV})}{P(E)}$$\n\nTo solve this, we must determine the terms $P(E \\mid \\text{de novo SNV})$ (the likelihood of the evidence given the de novo SNV hypothesis) and $P(E)$ (the marginal probability of the evidence).\n\nThe marginal probability $P(E)$ is found by applying the law of total probability over the set of all hypotheses:\n$$P(E) = P(E \\mid \\text{CNV})P(\\text{CNV}) + P(E \\mid \\text{de novo SNV})P(\\text{de novo SNV}) + P(E \\mid \\text{recessive})P(\\text{recessive})$$\n\nLet's calculate the likelihood of the evidence $E$ for each hypothesis. The problem provides the following parameters:\n- The fraction of true de novo SNV etiologies that are a de novo LoF in a constrained gene: $f = 0.60$.\n- The analytical sensitivity of the assay for detecting such LoF variants: $s = 0.98$.\n- The background probability of observing an incidental de novo LoF in a constrained gene when the etiology is *not* a de novo SNV: $r = 2 \\times 10^{-3}$.\n\n1.  **Likelihood for the de novo SNV hypothesis, $P(E \\mid \\text{de novo SNV})$**:\n    If the true etiology is a de novo SNV, the specific observation $E$ is made if the causal variant is of the type being looked for (a de novo LoF in a constrained gene) and the assay successfully detects it. The problem statement does not provide for a background rate of incidental findings in cases where the true etiology is a de novo SNV but of a different type (e.g., missense), so we follow the provided information strictly. The probability is the product of the fraction of cases that are of this type and the sensitivity of the test.\n    $$P(E \\mid \\text{de novo SNV}) = f \\times s = 0.60 \\times 0.98 = 0.588$$\n\n2.  **Likelihood for the non-de novo SNV hypotheses, $P(E \\mid \\text{CNV})$ and $P(E \\mid \\text{recessive})$**:\n    The problem states that for etiologies that are not de novo SNV (i.e., CNV or recessive), the probability of observing an incidental de novo LoF is $r$. The observation $E$ occurs if such an incidental variant arises and is detected. The detection probability is again the sensitivity $s$.\n    Therefore, for both the CNV and recessive hypotheses, the likelihood of observing $E$ is the same:\n    $$P(E \\mid \\text{CNV}) = r \\times s = (2 \\times 10^{-3}) \\times 0.98 = 0.00196$$\n    $$P(E \\mid \\text{recessive}) = r \\times s = (2 \\times 10^{-3}) \\times 0.98 = 0.00196$$\n\nNow, we can compute the marginal probability $P(E)$:\n$$P(E) = P(E \\mid \\text{de novo SNV})P(\\text{de novo SNV}) + P(E \\mid \\text{CNV})P(\\text{CNV}) + P(E \\mid \\text{recessive})P(\\text{recessive})$$\nSubstituting the values:\n$$P(E) = (0.588)(0.50) + (0.00196)(0.20) + (0.00196)(0.30)$$\nWe can factor the second and third terms:\n$$P(E) = (0.588)(0.50) + (0.00196)(0.20 + 0.30)$$\n$$P(E) = (0.588)(0.50) + (0.00196)(0.50)$$\n$$P(E) = 0.294 + 0.00098$$\n$$P(E) = 0.29498$$\n\nFinally, we compute the desired posterior probability $P(\\text{de novo SNV} \\mid E)$:\n$$P(\\text{de novo SNV} \\mid E) = \\frac{P(E \\mid \\text{de novo SNV}) P(\\text{de novo SNV})}{P(E)}$$\nThe numerator is the first term in our calculation of $P(E)$:\n$$P(E \\mid \\text{de novo SNV}) P(\\text{de novo SNV}) = 0.588 \\times 0.50 = 0.294$$\nSubstituting this and the value for $P(E)$:\n$$P(\\text{de novo SNV} \\mid E) = \\frac{0.294}{0.29498}$$\n$$P(\\text{de novo SNV} \\mid E) \\approx 0.9966777408637873...$$\n\nThe problem requires rounding the answer to $4$ significant figures.\n$$P(\\text{de novo SNV} \\mid E) \\approx 0.9967$$\nThis result indicates that given the strong evidence from the trio exome sequencing, the belief that a de novo SNV is the cause of the child's condition increases from a prior probability of $0.50$ to a posterior probability of approximately $0.9967$.", "answer": "$$\\boxed{0.9967}$$", "id": "5039762"}]}